Argentina has made an important step forward to protect local production of generics of an essential medicine to treat Hepatitis C. This brings significant advantages for Public Programs which procure the medicines. Buenos Aires, December 4, 2017. In Argentina, the INPI (National Institute of Industrial Property) rejected GILEAD PHARMASSET LLC patent application on Sofosbuvir prodrug, an essential medicine to treat HepC. The resolution PN 066898 of INPI
Lawsuits in India and Argentina seek to reduce drug costs by allowing generic versions of antiviral treatments. The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in those countries. In the 2000s,
Resistance to high prices for hepatitis C drugs is ongoing as five new challenges against patents have been filed in India and Argentina, according to sources. Those challenges aim at allowing the production and distribution of affordable generic versions of new hepatitis C medicines (direct-acting antivirals). According to a Médecins Sans Frontières (MSF, Doctors Without Borders) press release, on 13 February the Initiative for Medicines, Access & Kn
Physician, patient, and health justice groups including the Initiative for Medicines, Access and Knowledge (I-MAK) are mounting legal challenges to Gilead Sciences' patent to sofosbuvir in several middle-income countries including Argentina, Brazil, China, Russia and Ukraine. Read more...http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html...